September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The outcome of chronic diabetic macular oedema in patients treated with intravitreal Fluocinolone acetonide (Iluvien)
Author Affiliations & Notes
  • Ibraheem El-Ghrably
    Ophthalmology, James Cook University Hospital, Newcastle Upon-Tyne, United Kingdom
  • Footnotes
    Commercial Relationships   Ibraheem El-Ghrably, Alimera (R)
  • Footnotes
    Support  Grant support for conference, travel and accommodation
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3272. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ibraheem El-Ghrably; The outcome of chronic diabetic macular oedema in patients treated with intravitreal Fluocinolone acetonide (Iluvien). Invest. Ophthalmol. Vis. Sci. 2016;57(12):3272.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the efficacy and safety of Fluocinolone acetonide (Iluvien) implant in the treatment of patients with chronic DMO

Methods : Multicentre study of consecutive patients treated with Fluocinolone acetonide (Iluvien) for chronic DMO in 3 large UK Ophthalmic centres. Standardised information on all patients was prospectively collected using a jointly agreed database. Patients were seen 2-4 weeks post injection and then at 3, 6 and 12 months. The primary efficacy outcome measure was the change in central macular thickness (CMT) from base line measured by OCT.

Results : Fifty seven (57) patients were included. The mean age of patients was 62 years. The mean duration of diabetic macular oedema was 30.9 months. 25 of the patients had previous vitrectomy. The mean number of the previous anti-VEGF injections was 4.8. Out of the 57 patients included, 45 completed 3 months follow up, 34 completed 6 months and 22 patients completed one year follow-up. The mean change from base line CMT (452 µm) was -102 µm at month 3, -125 µm at month 6 and -126 at month 12.The mean increase in best-corrected visual acuity from base line (52.7 ETDRS letters) was 6.0 letters at month 3, 6.7 letters at month 6 and 5.1 letters at month 12.Five (5) patients needed intraocular pressure medications at month 3 and remained the same at month 6 and month 12. None needed glaucoma surgery. Two (2) patients with previous vitrectomy and a defect in the posterior capsule had a migrated Iluvien implant into the anterior chamber and both were retrieved using a 23g flute needle cannula and re inserted back to the vitreous cavity.

Conclusions : Treatment of DMO with Fluocinolone (Iluvien) led to anatomical and visual acuity improvement with an acceptable safety profile.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.